Outcome of COVID-19 in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors

INTRODUCTION: In this study, we aim to report the outcome of COVID-19 in chronic myeloid leukemia (CML) patients receiving tyrosine kinase inhibitor (TKI). METHOD: The data of 16 laboratory-confirmed COVID-19 patients with CML receiving TKI and age, gender, and comorbid disease matched COVID-19 pati...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:J Oncol Pharm Pract
Glavni autori: Başcı, Semih, Ata, Naim, Altuntaş, Fevzi, Yiğenoğlu, Tuğçe Nur, Dal, Mehmet Sinan, Korkmaz, Serdal, Namdaroğlu, Sinem, Baştürk, Abdülkadir, Hacıbekiroğlu, Tuba, Doğu, Mehmet Hilmi, Berber, İlhami, Dal, Kürşat, Erkurt, Mehmet Ali, Turgut, Burhan, Çağlayan, Murat, Ayvalı, Mustafa Okan, Çelik, Osman, Ülgü, Mustafa Mahir, Birinci, Şuayip
Format: Artigo
Jezik:Inglês
Izdano: SAGE Publications 2020
Teme:
Original Articles
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7506180/
https://ncbi.nlm.nih.gov/pubmed/32854573
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1078155220953198
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items